title: Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation.
abstract: Dexamethasone-induced hiccup (DIH) is an underrecognized symptom in patients with cancer, and little information is available about its treatment. The aims of this study were to investigate the feasibility of methylprednisolone rotation as treatment and to confirm the male predominance among those with cancer who experienced DIH during chemotherapy. Methods. Persons with cancer who experienced hiccups during chemotherapy treatment and who were receiving treatment with dexamethasone were presumed to have DIH. The following algorithmic practice was implemented for antiemetic corticosteroid use: rotation from dexamethasone to methylprednisolone in the next cycle and dexamethasone re-administration in the second cycle of chemotherapy after recognition of hiccups to confirm DIH. All other antiemetics except corticosteroid remained unchanged. Patients (n = 40) were recruited from eight cancer centers in Korea from September 2012 to April 2013. Data were collected retrospectively. Results. Hiccup intensity (numeric rating scale [NRS]: 5.38 vs. 0.53) and duration (68.44 minutes vs. 1.79 minutes) were significantly decreased after rotation to methylprednisolone, while intensity of emesis was not increased (NRS: 2.63 vs. 2.08). Median dose of dexamethasone and methylprednisolone were 10 mg and 50 mg, respectively. Thirty-four (85%) of 40 patients showed complete resolution of hiccups after methylprednisolone rotation in the next cycle. Of these 34 patients, 25 (73.5%) had recurrence of hiccups after dexamethasone re-administration. Compared with baseline values, hiccup intensity (NRS: 5.24 vs. 2.44) and duration (66.43 minutes vs. 22.00 minutes) were significantly attenuated after dexamethasone re-administration. Of the 40 eligible patients, 38 (95%) were male. Conclusion. DIH during chemotherapy could be controlled without losing antiemetic potential by replacing dexamethasone with methylprednisolone. We also identified a male predominance of DIH. Further prospective studies are warranted.
authors.affiliation: Department of Internal Medicine, Institute of Health Science, College of Medicine, Gyeongsang National University, Jinju, South Korea;
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Myoung Hee
authors.initials: MH
authors.lastname: Kang
authors.forename: Jung Hun
authors.initials: JH
authors.lastname: Kang
authors.forename: Se Hoon
authors.initials: SH
authors.lastname: Park
authors.forename: In Gyu
authors.initials: IG
authors.lastname: Hwang
authors.forename: Seong Yoon
authors.initials: SY
authors.lastname: Yi
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Choi
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Ji
authors.forename: Ha Yeon
authors.initials: HY
authors.lastname: Lee
authors.forename: Eduardo
authors.initials: E
authors.lastname: Bruera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006606:Hiccup / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003907:Dexamethasone; D008775:Methylprednisolone
keywords: Corticosteroids; Dexamethasone; Hiccup; Methylprednisolone